您好,欢迎来到上海士研管理咨询有限公司
士研峰会 士研智库 士研调研
嘉宾信息
范晓虎
范晓虎
所属职位: 联合创始人兼首席科学官
所属公司:

南京传奇生物科技公司

范晓虎博士是应用免疫学与基因治疗领域知名专家。1995年留日 2004年在加拿大知名多伦多病童医院工作期间在小儿血型不合心脏移植的研究方面取得世界级创新突破,在Nature Medicine发表原著论文首次阐明了人类B细胞免疫耐受机制,论证了婴幼儿在移植前无需考虑ABO血型相合的理论基础,引起了国际关注。这一重要研究成果改变了临床指南,多年来挽救了大量宝贵器官和患儿生命。

2014年7月回国加盟金斯瑞集团投身生物医药,2015年初创建金斯瑞子公司南京传奇生物,建立起了优秀的研发团队开发先进的CAR-T技术平台,首发治疗复发难治性多发骨髓瘤的产品LCAR-B38M取得国际领先成果。赢得强生公司与传奇公司就该产品合作开发全球市场的战略伙伴协议。2018年3月8日,LCAR-B38M产品获得中国第一个CAR-T细胞药物临床试验批件,2020年8月获得中国医药史第一个“突破性疗法”认证,建立了中国细胞治疗药物史上一系列重要里程碑。2018年5月30日,LCAR-B38M产品获得美国FDA临床试验批准顺利开始Ib/II期临床试验并于2019年获得FDA突破性疗法及欧盟EMA优先药物审评资格,有望成为下一个治疗骨髓瘤的“重磅药物”。目前传奇生物已拥有世界最大的细胞药物研发团队并转型为全产业链的生物医药企业,并作为CART行业领军企业成功赴美纳斯达克上市,范博士继续作为CSO领导传奇生物努力开发更多先进的CAR-T癌症治疗产品以及自主创新平台技术。

Dr. Fan is the co-founder of Legend Biotech and currently serves the company as the Chief Scientific Officer. Dr. Fan received his medical degree at Xi’an Jiaotong University in 1993 and worked as a surgical resident in the kidney Transplantation Centre of the university before he pursued his Ph.D. in applied immunology at Hiroshima University, Japan. He completed his postdoctoral training at the Hospital for Sick Children, University of Toronto, Canada where he became recognized as an expert in the field of the mechanism of human B cell tolerance.
Dr. Fan has been published in numerous peer-reviewed academic journals, including an original article published in Nature Medicine which lead to a major revision in the clinical guidelines of pediatric organ transplantation. Dr. Fan’s scientific achievement paved the way by showing that small children can be safely transplanted with ABO blood group mismatched organs, and saved many lives of infant patients. Dr. Fan was awarded the“New Key Opinion Leader”award by The Transplantation Society in 2006.
Dr. Fan founded Legend Biotech in 2015 and the company grew into a global leader in cancer immunotherapy in just 5 years. A bispecific BCMA-targeting CAR-T product Dr. Fan invented entered a global partnership with Janssen to co-develop the global markets. The product received breakthrough designation from the FDA and PRIME scheme from the EMA. Dr. Fan is now leading the world’s largest cell therapy R&D team and is devoted to inventing more innovative technologies for treating solid tumors and other diseases.

微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务